Last updated: February 15, 2026
Product Overview:
NDC 00093-8073 corresponds to a 100 mg dosage of sitagliptin phosphate tablets. Sitagliptin is an antidiabetic medication used mainly to improve glycemic control in adults with type 2 diabetes mellitus. Marketed under the brand name Januvia by Merck, it is part of the DPP-4 inhibitor class.
Market Landscape:
1. Market Size and Trends
- The global type 2 diabetes market reached approximately USD 87 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of about 9% through 2030.
- The U.S. accounts for over 40% of global sales, given the high prevalence of diabetes (about 37 million Americans as of 2021, per CDC).
- Januvia held a market share of approximately 27% in the oral antidiabetic drugs (OADs) segment in 2022.
- Competition includes drugs like Dapagliflozin (Farxiga), Liraglutide (Victoza), and Empagliflozin (Jardiance), which have gained market share through different mechanisms and formulations.
2. Regulatory Environment
- Approved by the FDA in 2006, sitagliptin has maintained a favorable safety profile.
- Patent protection expired in 2017, leading to increased generic competition entering the market. Several generic formulations are available from multiple manufacturers, reducing prices and affecting brand market share.
3. Reimbursement and Pricing Dynamics
- Steady reimbursements have been maintained for branded Januvia through pharmacy benefit managers (PBMs).
- Generics account for over 60% of prescriptions by volume since 2018, pressing prices downward.
- The retail price for brand-name Januvia tablets is approximately USD 480 per 30-count bottle (100 mg), but with discounts and insurer negotiations, the net price falls significantly.
Price Projections:
1. Existing Competition Effect
- The entry of generics has decreased median retail prices by approximately 65% since patent expiry. Currently, the average price for generics ranges from USD 200 to USD 250 per 30-count bottle.
- Brand-name Januvia's wholesale acquisition cost (WAC) declines to about USD 15 per tablet, or approximately USD 450 for a 30-day supply at 100 mg doses, but actual net prices are often lower for insured patients.
2. Future Price Trends
- Prices for generic sitagliptin are expected to stabilize around USD 200–USD 250 per month in the next 3-5 years, given current market dynamics.
- Brand-name prices are unlikely to recover significantly due to sustained generic competition, although slight upward adjustments could occur if new formulations, biosimilars, or fixed-dose combinations are introduced.
3. Impact of Biosimilars and Fixed-Dose Combinations
- No biosimilar options exist for sitagliptin alone at present; however, fixed-dose combinations with metformin (Janumet) or SGLT2 inhibitors could influence sitagliptin pricing and prescribing patterns.
- Such combinations could either increase or decrease the average price based on formulation and approval status.
4. Pricing in Emerging Markets
- Prices in developing countries range from USD 10–USD 50 per 30 tablets, influenced heavily by local patent status, regulatory policies, and volume discounts.
Market Entry and Commercial Strategies:
- For generic manufacturers: Opportunities exist to capture market share by offering quality formulations at reduced prices, especially targeting cost-sensitive geographies.
- For innovator companies: Maintaining differentiation through fixed-dose combinations or new delivery modalities (e.g., oral, injectable) could justify marginal price premiums.
| 5. Revenue Forecast (2023-2028): |
Year |
Estimated Prescriptions (million units) |
Average Net Price (USD) |
Projected Revenue (USD billion) |
| 2023 |
30 |
220 |
6.6 |
| 2024 |
32 |
210 |
6.7 |
| 2025 |
33 |
200 |
6.6 |
| 2026 |
34 |
195 |
6.6 |
| 2027 |
35 |
190 |
6.7 |
(Assumes continued market penetration and generic dominance; actual revenues depend on regulatory developments and market penetration rates.)
Key Takeaways:
- The market for sitagliptin (NDC 00093-8073) is mature, heavily impacted by patent expirations and generic competition.
- Current retail prices for generics have decreased significantly, with stabilization expected around USD 200–USD 250 per 30 tablets.
- Brand-name prices are under pressure, with limited potential for recovery outside niche indications or combination therapies.
- Market growth will likely depend on expansion into emerging markets and new formulation innovations rather than price increases.
FAQs
Q1: How has patent expiry affected sitagliptin pricing?
Patent expiry in 2017 led to a surge of generic entrants, reducing prices by approximately 65–70%. The generic market now dominates volume, limiting the ability for brand-name prices to recover.
Q2: What factors influence future sitagliptin prices?
Market saturation with generics, biosimilar or combination drug developments, and regional regulation impact prices. Pricing remains primarily dictated by manufacturing costs and competitive dynamics.
Q3: Are there opportunities for higher pricing within the sitagliptin market?
Limited in mature markets; only possible with novel formulations, fixed-dose combinations, or specialty indications. Vertical integration into combination therapies might sustain premium pricing in specific niches.
Q4: How does global pricing differ from U.S. markets?
Prices in emerging markets are significantly lower, often USD 10–USD 50 per 30 tablets, driven by local patent status, procurement policies, and volume discounts.
Q5: What is the outlook for new branded formulations of sitagliptin?
Potential exists with fixed-dose combinations or innovative delivery systems; however, regulatory approval and market acceptance are uncertain. Pricing in such cases may maintain slight premiums over generics.
References
[1] IQVIA. "Pharmaceutical Market Overview," 2022.
[2] CDC. "Statistics on Diabetes in the United States," 2021.
[3] EvaluatePharma. "Global Diabetes Market Trends," 2022.
[4] FDA. "Drug Approvals and Patent Information," 2017.
[5] GoodRx. "Drug Pricing Data," 2023.
